Collaboration Opportunities
As the sole agent for KHK's pharmaceutical development activities in North America, KKC is continually seeking collaborative opportunities that will support and add value to KHK's therapeutic platforms. Our key areas of interest include autoimmune disorders, inflammatory disorders and infectious diseases, as well as cancer, renal diseases and hematological disorders. KKC seeks collaborative partners from both the industrial and academic sector with novel targets and technologies that will facilitate our research and development efforts.
Antibody Development
Continuing its dedication to bringing innovative and effective new drugs to market, KHK has recently added human antibody therapeutics to its core technology portfolio with the development of the KM Mouse™. As a technology platform the KM Mouse™ is a powerful drug discovery tool, and our scientists at KKC are using the KM Mouse™ to generate unique, therapeutically active antibodies to novel targets.
For collaborative opportunities, KKC is interested in novel targets in infectious diseases and autoimmune/inflammatory diseases that are amenable to antibody-based targeting.
Technology Collaborations
In addition to seeking unique targets for our antibody-based projects, KKC is also interested in novel technology platforms that will complement our research and development efforts. Our interests include those technologies that will facilitate KKC's antibody development programs.
To contact KKC with a Collaboration Opportunity, please e-mail us at: Contact@kyowa-kirin-ca.com.
